<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05124353</url>
  </required_header>
  <id_info>
    <org_study_id>Neuroprotective 1/2021</org_study_id>
    <nct_id>NCT05124353</nct_id>
  </id_info>
  <brief_title>Early Administration of Cerebrolysin on the Outcome of Patients With Acute Stroke Undergoing EVT</brief_title>
  <official_title>Evaluation of the Effect of Early Administration of Neuroprotective Drug (Cerebrolysin) on the Outcome of Patients With Acute Ischemic Stroke Undergoing Endovascular Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pomeranian Medical University Szczecin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pomeranian Medical University Szczecin</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background:&#xD;
&#xD;
      Stroke is the third major cause of death and disability worldwide. It was shown that&#xD;
      combining early reperfusion therapy (thrombolysis and/or thrombectomy) with stroke unit care&#xD;
      and immediate rehabilitation have beneficial effects on the patient recovery and outcomes.&#xD;
      Cerebrolysin that was proven to have s neuroprotective and neurotrophic effects in vitro and&#xD;
      in vivo, administered in combination with endovascular therapy (EVT) could have a positive&#xD;
      impact on the prognosis and outcome of these patients.&#xD;
&#xD;
      Objectives:&#xD;
&#xD;
      To evaluate the impact of early administration of neuroprotective drug (Cerebrolysin) in&#xD;
      patient undergoing EVT on the outcome of patients diagnosed with acute ischemic stroke.&#xD;
&#xD;
      Methods:&#xD;
&#xD;
      100 patients will be recruited to the proposed study according to the inclusion criteria:&#xD;
&#xD;
      Inclusion criteria:&#xD;
&#xD;
      Acute ischemic stroke patients NIHSS&gt;8 Qualification for mechanical thrombectomy, without&#xD;
      previous thrombolysis. The patients will be randomized into 2 subgroups: G1(standard dose of&#xD;
      Cerebrolysin 30ml), - G2 (No Cerebrolysin).&#xD;
&#xD;
      The patients will be randomized into 2 subgroups: G1(standard dose of Cerebrolysin 30ml), -&#xD;
      G2 (No Cerebrolysin). Cerebrolysin will be administered immediately after randomization or at&#xD;
      the latest during the EVT procedure and will be continued for 10 days. After the EVT all&#xD;
      patients, depending on their clinical condition, will be hospitalized in ICU (intensive care&#xD;
      unit) or Neurology Department, where standard treatment and monitoring will be implemented,&#xD;
      as well as standard rehabilitation. Outcome assessments will include: the NIH Stroke Scale,&#xD;
      modified Rankin Score, pre MRS, IQ code, Geriatric Depression Scales, MoCA. Additionally, the&#xD;
      infarct volume of the control CT will be measured. The follow up should be performed on day&#xD;
      7( or discharge), 1 month, 3 months, 6 months. The duration of the study is planned forr: 12&#xD;
      -24 months&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Introduction:&#xD;
&#xD;
      Acute ischemic stroke is one of the main leading cause of death and disability in the world.&#xD;
      In proposed project we evaluate the impact of the combination of early reperfusion therapy&#xD;
      (thrombectomy) with early neuroproptective drug administration on treatment results in&#xD;
      patients with acute ischemic stroke. Cerebrolysin, which has been shown to have&#xD;
      neuroprotective and neurotrophic effects in vitro and in vivo, when administered early in&#xD;
      combination with early endovascular therapy may have a positive effect on the prognosis and&#xD;
      treatment outcomes of these patients. The proposed study, is approved by the Pomeranian&#xD;
      Medical University Bioethics Committee in Szczecin, Poland, will be also part of the&#xD;
      international CERECAP project investigating the co-application of neuroprotective and&#xD;
      reperfusion therapies (thrombolysis, thrombectomy) in patients with acute ischemic stroke.&#xD;
&#xD;
      Purpose of the project:&#xD;
&#xD;
      examining the impact of early cerebrolysin supply on the treatment effect in patients with&#xD;
      diagnosed acute ischemic stroke, qualified for endovascular treatment in the form of&#xD;
      thrombectomy&#xD;
&#xD;
      Hypothesis:&#xD;
&#xD;
      Cerebrolysin in early (up do 6 h) administration with combination of early (up to 6h)&#xD;
      endovascular therapy (thrombectomy) is beneficial for the patients with acute ischemic stroke&#xD;
      diagnosis.&#xD;
&#xD;
      Material and method 100 patients will be qualified for the proposed project. Study duration:&#xD;
      24 months.&#xD;
&#xD;
      Inclusion criteria for the study diagnosis of acute ischemic stroke qualification for&#xD;
      endovascular treatment in the form of thrombectomy&#xD;
&#xD;
      Criteria for exclusion from the study:&#xD;
&#xD;
      Patient qualified for thrombolysis Patients under 18 years of age pregnancy Kidney failure&#xD;
      Epilepsy History of allergy to cerebrolysin&#xD;
&#xD;
      Study design:&#xD;
&#xD;
      After prior randomization to the group, patients will be divided into group G1 (cerebrolysin&#xD;
      supply) and group G2 (standard treatment, without cerebrolysin supply).&#xD;
&#xD;
      In group G1, cerebrolysin will be administered immediately after qualifying for the study&#xD;
      (i.e. up to 6 hours after the onset of symptoms) and continued for the next 10 days at a dose&#xD;
      of 30 ml i.v.&#xD;
&#xD;
      Patients from both groups G1 and G2 will undergo thrombectomy treatment, and then, depending&#xD;
      on the clinical condition, hospitalized in the Intensive Care Unit or the Department of&#xD;
      Neurology with the Stroke Department.&#xD;
&#xD;
      During the hospitalization, the standard and typical care for both departments will be&#xD;
      continued.&#xD;
&#xD;
      Treatment results will be assessed using:&#xD;
&#xD;
      NIH, Modified Rankin Scale, preMRS, IQ code, Geriatric Depression Scale and MoCA.&#xD;
&#xD;
      Routine checkups for computed tomography will also undergo analysis for treatment evaluation&#xD;
      (e.g. stroke volume). Patients' condition will be assessed after 1, 3 and 6 months.&#xD;
&#xD;
      The results obtained in this way will be statistically analyzed and presented in the form of&#xD;
      articles in medical journals.&#xD;
&#xD;
      Expected benefits:&#xD;
&#xD;
        -  examination of the influence of early cerebrolysin supply on the treatment effect in&#xD;
           patients undergoing thrombectomy after acute ischemic stroke diagnosis&#xD;
&#xD;
        -  development of the cerebrolysin supply protocol in patients with acute ischemic stroke&#xD;
           diagnosis&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 27, 2021</start_date>
  <completion_date type="Anticipated">April 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2023</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survival</measure>
    <time_frame>6 months</time_frame>
    <description>survival rate within first 6 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>NIHSS</measure>
    <time_frame>day 1</time_frame>
    <description>NIH Stroke Scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>NIHSS</measure>
    <time_frame>month 3</time_frame>
    <description>NIH Stroke Scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>NIHSS</measure>
    <time_frame>month 6</time_frame>
    <description>NIH Stroke Scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rankin</measure>
    <time_frame>day 1</time_frame>
    <description>modified Rankin Score</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rankin</measure>
    <time_frame>month 3</time_frame>
    <description>modified Rankin Score</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rankin</measure>
    <time_frame>month 6</time_frame>
    <description>modified Rankin Score</description>
  </primary_outcome>
  <primary_outcome>
    <measure>pre MRS</measure>
    <time_frame>day 1</time_frame>
    <description>modified pre Rankin Score</description>
  </primary_outcome>
  <primary_outcome>
    <measure>pre MRS</measure>
    <time_frame>month 3</time_frame>
    <description>modified pre Rankin Score</description>
  </primary_outcome>
  <primary_outcome>
    <measure>pre MRS</measure>
    <time_frame>month 6</time_frame>
    <description>modified pre Rankin Score</description>
  </primary_outcome>
  <primary_outcome>
    <measure>IQ code</measure>
    <time_frame>month 3</time_frame>
    <description>IQ code</description>
  </primary_outcome>
  <primary_outcome>
    <measure>IQ code</measure>
    <time_frame>month 6</time_frame>
    <description>IQ code</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geriatric Depression Scales</measure>
    <time_frame>month 3</time_frame>
    <description>Geriatric Depression Scales</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geriatric Depression Scales</measure>
    <time_frame>month 6</time_frame>
    <description>Geriatric Depression Scales</description>
  </primary_outcome>
  <primary_outcome>
    <measure>IV</measure>
    <time_frame>10 days</time_frame>
    <description>infarct volume of the control CT</description>
  </primary_outcome>
  <primary_outcome>
    <measure>modified treatment in cerebral infarction (mTICI score)</measure>
    <time_frame>1 month</time_frame>
    <description>measure the reperfusion grade post thrombectomy - radiological imaging</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Stroke, Acute, Ischemic</condition>
  <arm_group>
    <arm_group_label>G1 : Treatment Group (TG)r</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in TG receive neuroprotective drug: standard dose of Cerebrolysin 30ml i.v. in the first 6 hours after first symptoms. After EVT the administration is continued for 10 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>G2 : Control Group (CG)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients in CG receive no additional i.v. treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cerebrolysin</intervention_name>
    <description>Cerebrolysin 30ml i.v., administrated in first 6 hours after stroke onset and fo 10 day afterwards in Neurology Department or ICU conditions.</description>
    <arm_group_label>G1 : Treatment Group (TG)r</arm_group_label>
    <other_name>neuroprotective treatment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  acute ischemic stroke diagnosis,&#xD;
&#xD;
          -  qualification for mechanical thrombectomy, without previous thrombolysis&#xD;
&#xD;
          -  age &gt;18&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  age &lt;18&#xD;
&#xD;
          -  pregnancy&#xD;
&#xD;
          -  cerebrolysin allergy&#xD;
&#xD;
          -  epilepsy&#xD;
&#xD;
          -  renal failure&#xD;
&#xD;
          -  thrombolysis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Konrad Jarosz</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pomeranian Medical Univerisity</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Klaudyna Kojder</last_name>
    <phone>+48692581426</phone>
    <phone_ext>+48</phone_ext>
    <email>klaudynakojder@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Pomeranian Medical University, University Hospital no.1</name>
      <address>
        <city>Szczecin</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Klaudyna Kojder</last_name>
      <phone>+48692581426</phone>
      <phone_ext>+48</phone_ext>
      <email>klaudynakojder@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Klaudyna Kojder</last_name>
      <email>klaudynakojder@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Agata Andrzejewska</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joanna So≈Çek-Pastuszka</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anna Bajer-Czajkowska</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marta Masztalewicz</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Artur Reginia</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>June 25, 2021</study_first_submitted>
  <study_first_submitted_qc>November 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2021</study_first_posted>
  <last_update_submitted>November 7, 2021</last_update_submitted>
  <last_update_submitted_qc>November 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Pomeranian Medical University Szczecin</investigator_affiliation>
    <investigator_full_name>Klaudyna Kojder</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>acute.stroke</keyword>
  <keyword>ischemic stroke</keyword>
  <keyword>neuroprotection</keyword>
  <keyword>treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cerebrolysin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

